Core Viewpoint - Meihua Biotech has successfully completed the acquisition of the amino acid business and assets from Concord Fermentation, enhancing its product and business structure in the synthetic biology sector [1]. Group 1: Acquisition Details - The acquisition was finalized on July 1, 2025, with a transaction price of approximately 16.8 billion Japanese yen, equivalent to about 833 million RMB [1]. - The final transaction price was adjusted based on the cash reserves and working capital of the target assets at the time of closing, which included an estimated cash amount of 11.3 billion Japanese yen (approximately 560 million RMB) [1]. - Concord Fermentation is recognized as a leader in biotechnology and fermentation, focusing on high-quality amino acids and other synthetic biology products [1]. Group 2: Business Expansion - The acquisition allows Meihua Biotech to diversify its product offerings by adding various new amino acid products and strains, enhancing its fermentation and refinement capabilities for high-value pharmaceutical amino acids [1]. - The company will also gain production capabilities and intellectual property for three types of Human Milk Oligosaccharides (HMO) through the integration of a precision fermentation platform [1]. - The acquisition supports the company's strategy to expand its industrial footprint internationally by acquiring multiple domestic and foreign operational entities [1]. Group 3: Financial Performance - In Q1 2025, the feed amino acid segment generated revenue of 2.939 billion RMB, accounting for approximately 46.9% of total revenue, marking a year-on-year increase of 6.68% [2]. - The growth in this segment is attributed to the rise in both volume and price of lysine, as well as increased sales of threonine, positioning it as a potential new growth driver for the company [2].

中化新网讯 6月26日，中国科学院院士、天津大学教授元英进，合成生物学领军者约翰·康伯斯，欧洲科 学院院士、曼彻斯特大学教授蔡毅之，与天津大学历届iGEM团队成员在津共聚"iGEM中国20年"学术论 坛，共同探讨合成生物学未来发展方向。 约翰·康伯斯在活动中做了题为"合成生物学：通过基因读、写、编辑打造可持续的未来"的报告。他指 出，过去十年间，合成生物学已从一个小众科学领域发展成为潜力巨大的活跃产业，从基因编辑到合成 基因组学等关键技术的进步，推动了制药、农业、材料及能源等行业的可持续发展与创新。他还表示， 初创企业与风险投资的进入起到了加速创新的作用，有助于构建可持续的生物经济体系，学术界、产业 界与政府间的全球协作也在加速这一进程。 天津大学作为最早把这项国际赛事引入中国的高校，也开设了"基因组设计合成"这门本科生课程，并于 2017年设立合成生物学专业，开始招收本科生；2025年成立合成生物学院。经过十几年的发展，天津大 学合成生物学从零起步走到世界科技前沿，牵头建设合成生物技术全国重点实验室，近三年合成生物学 领域研究论文发表量居全球第一。 iGEM竞赛是合成生物学领域的国际顶级学术性竞赛，最早由美 ...

Core Insights - The article discusses the launch of the "Synthetic Human Genome Project" (SynHG), led by Professor Jason Chin from the University of Oxford, with funding of £10 million from the Wellcome Trust, aiming to chemically synthesize a complete human genome [1][2] - The project is expected to develop foundational tools and methods that will support future research in synthetic biology, potentially leading to new discoveries about how cells utilize their genomes [2][3] Group 1: Project Overview - SynHG is the first of its kind globally, with a goal to construct a complete human genome through chemical synthesis [1] - The project aims to establish a technical framework within five years and to synthesize a complete human chromosome within 5-10 years, facing significant scientific challenges [2] Group 2: Scientific Implications - Professor Jason Chin emphasizes that the ability to synthesize large genomes could fundamentally change the understanding of genomic biology and expand the capabilities of biotechnology and medicine [3] - The project is not about creating life but focuses on understanding gene expression regulation mechanisms [3] Group 3: Future Directions and Events - The upcoming "Synthetic Biology and Green Bio-Manufacturing Conference" (SynBioCon 2025) will take place from August 20-22 in Ningbo, Zhejiang, focusing on the intersection of AI and bio-manufacturing [4][5] - The conference will explore trends in bio-manufacturing, innovative technologies, and the potential for technology transfer and talent acquisition in the industry [4]

Core Viewpoint - The establishment of the AI4S synthetic biology intelligent research platform by Anhui Normal University, University of Science and Technology of China, and Wuhu Yijiang District aims to advance key technologies in synthetic biology, focusing on gene design, enzyme optimization, and biomanufacturing applications in various strategic emerging industries [1][6][10]. Group 1: Platform Overview - The AI4S platform will collaborate with over 20 enterprises and medical institutions, emphasizing breakthroughs in genome design and enzyme molecular modification [1][6]. - The platform integrates AI technology with automated experimental equipment to enhance experimental efficiency and data collection through high-throughput operations [3][8]. Group 2: Research Directions - The platform focuses on six major research areas: gene circuit design, enzyme discovery and optimization, metabolic pathway exploration, synthetic biology big data analysis, artificial cell factory creation, and biopharmaceutical synthesis [1][6]. - It aims to address critical challenges in biomanufacturing, including efficient gene design, experimental automation, data-driven optimization, and industrial-scale production [7][10]. Group 3: Technological Integration - The platform will create an integrated AI simulation and experimental validation system, combining high-performance computing and machine learning with experimental data [3][9]. - It will support virtual screening, experimental validation, and the establishment of cell factory models, enhancing the product development lifecycle [3][10]. Group 4: Industry Landscape - Multiple institutions in China have established similar synthetic biology platforms, including the Shenzhen Institute of Advanced Technology and Peking University, indicating a growing trend in the sector [4][6]. - Companies like BGI, Huaheng Biotechnology, and others are adopting AI and automated fermentation optimization platforms to accelerate product development [11]. Group 5: Future Prospects - With increasing policy support and industry demand, more institutions are expected to enter the field of synthetic biology and AI integration [12]. - The upcoming SynBioCon 2025 conference will focus on AI and biomanufacturing, exploring technological innovations and industry trends [14][16].

Core Viewpoint - The article discusses the innovative production and application of spermidine, a natural polyamine with significant potential in anti-aging and cardiovascular disease prevention, through synthetic biology techniques developed by a research team at Sichuan University [1][2]. Group 1: Spermidine Production Challenges - Spermidine is recognized as a promising bioactive molecule, but its high production costs have hindered large-scale industrial application [1][2]. - Traditional extraction methods yield low purity (only 1% from wheat germ) and are inefficient, while chemical synthesis is costly, leading to market domination by foreign companies [2][3]. Group 2: Technological Innovations - The research team employs machine learning algorithms to simulate yeast metabolic networks, significantly enhancing spermidine synthesis efficiency [3]. - A breakthrough in the discovery of an extracellular secretion mechanism allows spermidine to be actively expelled from cells, reducing energy consumption and improving purity during extraction [4]. Group 3: Industry Collaboration and Education - The collaboration between academia and industry enables students to engage in practical applications, bridging the gap between laboratory research and market needs [4][8]. - The establishment of a project-based learning model in universities aims to cultivate versatile talents for the industry [4][9]. Group 4: Market Potential and Policy Support - Spermidine is positioned to drive multiple billion-dollar industries, with ongoing clinical trials in the pharmaceutical sector and product development in the food industry [6][7]. - Chengdu is emerging as a hub for synthetic biology, with supportive policies from various provinces to facilitate technology transfer and commercialization [7][8]. Group 5: Future Outlook - The global economic impact of synthetic biology is projected to yield $2-4 trillion annually between 2030 and 2040, indicating a significant opportunity for industries leveraging these technologies [6]. - The integration of academic research, industry needs, and supportive policies is expected to enhance the domestic production of critical bioactive substances like spermidine, contributing to public health initiatives [8][9].

Core Viewpoint - Zhejiang Rongrui Technology Co., Ltd. has completed nearly 100 million yuan in Pre-A round financing, which will primarily be used to accelerate product pipeline development and continue the industrialization and commercialization process [1] Company Overview - Founded in 2022, Rongrui Technology focuses on synthetic biology as its core technology, integrating the latest advancements in artificial intelligence to develop disruptive technologies for artificial life and functional molecules [2] - The company aims to achieve green biological manufacturing in areas such as health food ingredients and high-value chemicals, while also reducing product costs and improving quality [2] - The product pipeline includes dozens of successfully developed products, such as important industrial enzyme varieties (lipase, nitrile hydratase, nitrile hydrolase, amide enzyme), pharmaceuticals, pesticides, high-value fine chemicals (chiral alcohols, chiral amines, chiral non-natural amino acids, amide compounds), as well as health oils, new structural esters, vitamins, and sugar substitutes [2] - The company has established multiple collaborations with leading enterprises in its niche [2] Industry Event - The 4th Synthetic Biology and Green Biological Manufacturing Conference (SynBioCon 2025) will be held from August 20-22 in Ningbo, Zhejiang, focusing on the "1+4" theme: AI + Biological Manufacturing [3] - The conference will cover four major application areas: green chemicals and new materials, future food, future agriculture, and beauty raw materials, inviting international leading companies, representative industrial experts, government, parks, capital, associations, and alliances to explore the development trends of the biological manufacturing industry during the 14th Five-Year Plan [3] - The event aims to promote the transfer and transformation of scientific and technological achievements, product scaling, and talent acquisition [3]

Core Viewpoint - Rongrui Technology focuses on green manufacturing in fields such as industrial enzyme preparations, health foods, pharmaceutical chemicals, and functional new materials, leveraging synthetic biology and artificial intelligence to develop disruptive technologies for green bio-manufacturing [1][2]. Group 1: Company Overview - Rongrui Technology was established in 2022 and has successfully developed dozens of products, including key industrial enzyme varieties such as lipase and amide enzymes, as well as high-value fine chemicals and health products [1]. - The company has formed multiple collaborations with leading enterprises in its niche sectors [1]. Group 2: Recent Financing - Rongrui Technology recently completed nearly 100 million yuan in Pre-A round financing, led by PwC Capital and Dinghui VGC, with Kai Cheng Capital serving as the exclusive financial advisor [1]. - The funds raised will primarily be used to accelerate product pipeline development and continue the industrialization and commercialization processes [1]. Group 3: Management and Investor Insights - The CEO of Rongrui Technology expressed gratitude for the support from investors and emphasized the company's commitment to enhancing technology, production facilities, and commercial channels to ensure sustained growth [2]. - Investors from PwC Capital and Dinghui VGC highlighted the team's extensive industrial experience and solid R&D foundation, expressing confidence in the company's growth prospects and its ability to create social value through its strong technology platform [3].

Core Viewpoint - The article discusses the advancements in synthetic biology tools for customizing yeast cell factories, highlighting their potential in producing high-value compounds efficiently [3]. Group 1: Innovative Tools for Yeast Cell Factories - The paper titled "Innovative tools for customized yeast cell factory" outlines significant progress in synthetic biology tools, including genome editing, computational tools, adaptive laboratory evolution, and standardization of biological DNA components [3]. - These tools aim to provide practical guidelines for the effective development of customized yeast cell factories [3]. Group 2: Genome Editing Tools - Genome editing has evolved from single-gene editing to simultaneous multi-gene editing, with CRISPR-Cas systems enabling precise modifications in yeast genomes, including knockouts, insertions, and replacements [6]. - New variants of CRISPR-Cas, such as base editing and prime editing, allow for single nucleotide changes to alter gene functions [6]. Group 3: Computational Tools - Computational tools, including metabolic modeling and the integration of omics technologies, guide engineering strategies and expected flux adjustments [7]. - Genome-scale metabolic models (GEMs) have been widely applied in yeast metabolic engineering, with large-scale kinetic models playing a crucial role in designing and understanding metabolic reactions [7]. Group 4: Adaptive Laboratory Evolution - Adaptive laboratory evolution (ALE) is a powerful strategy for enhancing yeast strain performance by applying selective pressure over generations, leading to the emergence of more adaptive strains [8]. - Combining ALE with whole-genome sequencing helps identify beneficial mutations and provides insights into the genetic basis of adaptability [8]. Group 5: Standardization of Biological DNA Components - The increasing complexity of yeast cell factory designs necessitates precise control and regulation of biological components, gene circuits, or biological systems [9]. - Synthetic biology offers standardized biological components, allowing researchers to assemble these components into complex systems with predictable behaviors [9].

全球政策进展 | 上海市 2025 年度关键技术研发计划 "合成生物学 "项目立项清单 | 序号 | 1 | | --- | --- | | 项目编号 | 25HC2810100 | | | 基于喷墨打印微阵列芯片的高通量高精度 | | 项目名称 | 低成本长片段核酸合成 | | 项目承担单位 | 上海迪赢生物科技有限公司 | | 项目负责人 | 张满仓 | | 项目实施周期 | 2025.08.01-2028.07.31 | | 序号 | 2 | | 项目编号 | 25HC2810200 | | 项目名称 | 高通量长片段 DNA 酶促合成系统研发 | | 项目承担单位 | 上海人工智能研究院有限公司 | | 项目负责人 | 夏 凯 | | 项目实施周期 | 2025.08.01-2028.07.31 | | 序号 | 3 | 项目编号 25HC2810300 项目名称 重要天然产物生物合成功能元件挖掘及共 享元件库的构建 项目承担单位 上海中医药大学 项目负责人 陈万生 项目实施周期 2025.08.01-2028.07.31 序号 4 项目编号 25HC2810400 项目名称 生物合成新元件的挖掘表征 ...

"此次大会以'发展合成生物，培育未来产业'为主题，恰逢其时，意义深远。"中国生物发酵产业协会理 事长于学军说，"我们应聚焦关键，精准发力。一是强化科技创新引领，持续加大投入，鼓励高校、科 研机构与企业携手，开展联合攻关，突破关键技术瓶颈，释放创新活力，提升关键领域的核心竞争力， 让科技创新成为产业发展的强大引擎；二是促进产业协同发展，加强产业链上下游企业间的合作，形成 产业集群效应，推动合成生物学技术在医药、食品、农业、化工、能源等多领域的广泛应用，实现跨产 业的深度融合与协同发展，构建起互利共赢的产业生态；三是加强人才培养与引进，合成生物学作为一 门交叉学科，对复合型人才的需求迫切，应加强高校相关专业建设，完善人才培养体系，同时积极引进 海外高层次人才，为产业发展注入源头活水，提供坚实的人才保障；四是完善政策生态体系，政府部门 需精准施策，制定针对性政策，在税收优惠、财政补贴、项目支持等方面给予产业更多扶持，为合成生 物学产业的茁壮成长创造良好的政策环境，助力产业腾飞。" 本报讯 （记者 闫 利）日前，2025合成生物学技术创新发展大会在江苏宜兴举行。大会以"发展合成生 物 培育未来产业"为主题，8位两院院 ...